Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tandem Diabetes Care (TNDM) Equity Average (2016 - 2025)

Historic Equity Average for Tandem Diabetes Care (TNDM) over the last 12 years, with Q3 2025 value amounting to $133.1 million.

  • Tandem Diabetes Care's Equity Average fell 4354.19% to $133.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.1 million, marking a year-over-year decrease of 4354.19%. This contributed to the annual value of $288.4 million for FY2024, which is 2346.79% down from last year.
  • Per Tandem Diabetes Care's latest filing, its Equity Average stood at $133.1 million for Q3 2025, which was down 4354.19% from $144.3 million recorded in Q2 2025.
  • Over the past 5 years, Tandem Diabetes Care's Equity Average peaked at $443.5 million during Q2 2022, and registered a low of $133.1 million during Q3 2025.
  • Over the past 5 years, Tandem Diabetes Care's median Equity Average value was $329.7 million (recorded in 2021), while the average stood at $318.0 million.
  • In the last 5 years, Tandem Diabetes Care's Equity Average surged by 6901.92% in 2021 and then plummeted by 4354.19% in 2025.
  • Tandem Diabetes Care's Equity Average (Quarter) stood at $411.4 million in 2021, then rose by 4.74% to $430.9 million in 2022, then fell by 27.17% to $313.8 million in 2023, then fell by 20.21% to $250.4 million in 2024, then plummeted by 46.84% to $133.1 million in 2025.
  • Its Equity Average was $133.1 million in Q3 2025, compared to $144.3 million in Q2 2025 and $209.2 million in Q1 2025.